Entrada Therapeutics (TRDA) Competitors

Entrada Therapeutics (NASDAQ:TRDA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Which has more risk and volatility, TRDA or ORIC?

Entrada Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.

Does the media refer more to TRDA or ORIC?

In the previous week, Oric Pharmaceuticals had 16 more articles in the media than Entrada Therapeutics. MarketBeat recorded 18 mentions for Oric Pharmaceuticals and 2 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.90 beat Oric Pharmaceuticals' score of 0.33 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer TRDA or ORIC?

Entrada Therapeutics currently has a consensus price target of $25.67, suggesting a potential upside of 318.02%. Oric Pharmaceuticals has a consensus price target of $17.63, suggesting a potential upside of 80.95%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Oric Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Which has stronger earnings and valuation, TRDA or ORIC?

Entrada Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$210.78M	1.11	$65.63M	-$1.78	-3.45
Oric Pharmaceuticals	N/A	N/A	-$127.85M	-$1.89	-5.15

Is TRDA or ORIC more profitable?

Oric Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-92.30%	-17.81%	-14.55%
Oric Pharmaceuticals	N/A	-51.75%	-47.09%

Do institutionals and insiders hold more shares of TRDA or ORIC?

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Entrada Therapeutics beats Oric Pharmaceuticals on 11 of the 16 factors compared between the two stocks.